BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 11302795)

  • 1. Interactions of posaconazole and flucytosine against Cryptococcus neoformans.
    Barchiesi F; Schimizzi AM; Najvar LK; Bocanegra R; Caselli F; Di Cesare S; Giannini D; Di Francesco LF; Giacometti A; Carle F; Scalise G; Graybill JR
    Antimicrob Agents Chemother; 2001 May; 45(5):1355-9. PubMed ID: 11302795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
    Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
    Schwarz P; Dromer F; Lortholary O; Dannaoui E
    Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans.
    Barchiesi F; Gallo D; Caselli F; Di Francesco LF; Arzeni D; Giacometti A; Scalise G
    J Antimicrob Chemother; 1999 Jul; 44(1):65-70. PubMed ID: 10459811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of Cryptococcal meningitis with a combination of liposomal amphotericin B, flucytosine and posaconazole: two case reports.
    Esposito V; Viglietti R; Gargiulo M; Parrella R; Onofrio M; Sangiovanni V; Ambrosino D; Chirianni A
    In Vivo; 2009; 23(3):465-8. PubMed ID: 19454515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pulmonary cryptococcosis treated by combination therapy of fluconazole plus flucytosine].
    Tanaka K; Kohno S; Maesaki S; Mitsutake K; Miyazaki H; Miyazaki T; Tomono K; Kaku M; Koga H; Hara K
    Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31(12):1528-33. PubMed ID: 8121088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection.
    Barchiesi F; Spreghini E; Schimizzi AM; Maracci M; Giannini D; Carle F; Scalise G
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3312-6. PubMed ID: 15328090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp.
    Srimuang S; Prariyachatigul C; Chaiprasert A; Rungsipanuratn W; Tanphaichitra D
    J Med Assoc Thai; 2000 Jan; 83(1):57-60. PubMed ID: 10710870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans.
    Barchiesi F; Schimizzi AM; Caselli F; Giannini D; Camiletti V; Fileni B; Giacometti A; Di Francesco LF; Scalise G
    J Antimicrob Chemother; 2001 Dec; 48(6):769-73. PubMed ID: 11733459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans.
    Hossain MA; Maesaki S; Mitsutake K; Kakeya H; Sasaki E; Tomono K; Tashiro T; Kohno S
    J Antimicrob Chemother; 1999 Dec; 44(6):827-9. PubMed ID: 10590286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans.
    Nguyen MH; Barchiesi F; McGough DA; Yu VL; Rinaldi MG
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1691-5. PubMed ID: 7486902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
    Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
    Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2862-4. PubMed ID: 11557481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
    Pfaller M; Zhang J; Messer S; Tumberland M; Mbidde E; Jessup C; Ghannoum M
    Diagn Microbiol Infect Dis; 1998 Nov; 32(3):191-9. PubMed ID: 9884835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flucytosine and cryptococcosis: which in vitro test is the best predictor of outcome?
    Viviani MA; Esposto MC; Cogliati M; Tortorano AM
    J Chemother; 2003 Apr; 15(2):124-8. PubMed ID: 12797387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of 5-flucytosine and capsule-binding monoclonal antibody in the treatment of murine Cryptococcus neoformans infections and in vitro.
    Feldmesser M; Mukherjee J; Casadevall A
    J Antimicrob Chemother; 1996 Mar; 37(3):617-22. PubMed ID: 9182119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
    Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
    J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
    Schwarz P; Janbon G; Dromer F; Lortholary O; Dannaoui E
    Antimicrob Agents Chemother; 2007 Jan; 51(1):383-5. PubMed ID: 17043122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates.
    Schwarz P; Dromer F; Lortholary O; Dannaoui E
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3361-4. PubMed ID: 14506059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis.
    Nguyen MH; Najvar LK; Yu CY; Graybill JR
    Antimicrob Agents Chemother; 1997 May; 41(5):1120-3. PubMed ID: 9145879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.